This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More
The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. … Read More
Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial. Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More
Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. The trial This Phase IIb clinical trial will focus on first-line… Read More
AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More
The American Association for Cancer Research (AACR) Annual Meeting 2023 will be held April 14-19 at the Orange County Convention Center in Orlando, Florida. The meeting is the focal point of the American cancer research community, where scientists, clinicians, health care professionals, survivors, patients, and advocates share the… Read More
Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells. CircRNAs represent an… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The drug discovery industry has hit the ground running in 2023 with… Read More
It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. Professor Uğur Şahin, Chief Executive… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma. Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More
CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this new on-demand… Read More
CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron… Read More
Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More
News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More
Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer. Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More
The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer. BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More
